Phenotypic and Immunologic Comparison of Clade B Transmitted/founder and Chronic HIV-1 Envelope Glycoproteins
Overview
Authors
Affiliations
Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal barriers is responsible for the vast majority of new infections. This relatively inefficient process results in the transmission of a single transmitted/founder (T/F) virus, from a diverse viral swarm in the donor, in approximately 80% of cases. Here we compared the biological activities of 24 clade B T/F envelopes (Envs) with those from 17 chronic controls to determine whether the genetic bottleneck that occurs during transmission is linked to a particular Env phenotype. To maximize the likelihood of an intact mucosal barrier in the recipients and to enhance the sensitivity of detecting phenotypic differences, only T/F Envs from individuals infected with a single T/F variant were selected. Using pseudotyping to assess Env function in single-round infectivity assays, we compared coreceptor tropism, CCR5 utilization efficiencies, primary CD4(+) T cell subset tropism, dendritic cell trans-infections, fusion kinetics, and neutralization sensitivities. T/F and chronic Envs were phenotypically equivalent in most assays; however, T/F Envs were modestly more sensitive to CD4 binding site antibodies b12 and VRC01, as well as pooled human HIV Ig. This finding was independently validated with a panel of 14 additional chronic HIV-1 Env controls. Moreover, the enhanced neutralization sensitivity was associated with more efficient binding of b12 and VRC01 to T/F Env trimers. These data suggest that there are subtle but significant structural differences between T/F and chronic clade B Envs that may have implications for HIV-1 transmission and the design of effective vaccines.
Luthuli B, Gounder K, Deymier M, Dong K, Balazs A, Mann J Virology. 2023; 583:14-26.
PMID: 37084644 PMC: 10208420. DOI: 10.1016/j.virol.2023.04.001.
Sugrue E, Wickenhagen A, Mollentze N, Aziz M, Sreenu V, Truxa S PLoS Pathog. 2022; 18(11):e1010973.
PMID: 36399512 PMC: 9718408. DOI: 10.1371/journal.ppat.1010973.
Rindler A, Kuster H, Neumann K, Leemann C, Braun D, Metzner K Viruses. 2021; 13(3).
PMID: 33806576 PMC: 8000554. DOI: 10.3390/v13030404.
HIV-1 Envelope Glycosylation and the Signal Peptide.
Lambert G, Upadhyay C Vaccines (Basel). 2021; 9(2).
PMID: 33669676 PMC: 7922494. DOI: 10.3390/vaccines9020176.
HIV-1 Entry and Prospects for Protecting against Infection.
Bruxelle J, Trattnig N, Mureithi M, Landais E, Pantophlet R Microorganisms. 2021; 9(2).
PMID: 33499233 PMC: 7911371. DOI: 10.3390/microorganisms9020228.